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Evidence for Activity of GBR830 investigator's judgment) and IgE level (>500 vs <500 U/mL). Biopsies were collected for biomarker measurement. RESULTS: For subjects treated with at least one dose of GBR830 (n546), baseline clinical scores did not show marked differences according to AD subtype or IgE level. Nonetheless, decreases in SCORAD were observed during the study regardless of AD subtype or IgE level. Responses were observed shortly after the first dose of GBR830 and maintained through the second dose and beyond. Eotaxins were analyzed for subjects with skin biopsies (n529). Baseline CCL18 levels were numerically greater in subjects with Extrinsic vs Intrinsic AD (P<.05), but levels for CCL17 and CCL26 were not different. Post-treatment eotaxin levels did not change. CONCLUSIONS: GBR830 treatment showed clinical benefit in subjects, regardless of AD subtype or IgE level. Reductions in SCORAD clinical scores were observed throughout the treatment period. RATIONALE: Allergists/Immunologists use steroids judiciously to treat atopic dermatitis (AD), allergic rhinitis, and asthma. While their efficacy is widely appreciated, total topical steroid burden (cutaneous, inhaled, intranasal) is less monitored and side effects rarely addressed. We sought to validate a simplified electronic medical record (EMR) tool to improve documentation of total steroid burden (SB) and education of steroid effect. METHODS: A SB-monitoring tool was used in real time for 37 AD patient encounters. Data collected included corticosteroid type, potency, frequency, side effects, intervention, and patient counseling. A physician satisfaction survey measured satisfaction, and impact on length of patient visit. RESULTS: Thirty-seven AD encounters were assessed in 30 patients; 16(53.3%) female and average age of 27 years. Of 37 encounters using topical corticosteroids (TCS), 10 were also using inhaled and 3 intranasal corticosteroids. Four patients (13%) on TCS had at least one of the following: telangiectasia, atrophy, striae, hair growth, pigment changes, rosacea, and easy bruisability. One patient on intranasal corticosteroids had nosebleed and nasal dryness. There were no documented side effects for the inhaled. Thirty encounters (81%) had an intervention; 4 decreased dose, 3 decreased potency and 3 discontinued TCS. Twenty-five encounters had patient counseling. Physician satisfaction survey demonstrated 90% (10/11) found the tool extremely useful/useful and were extremely satisfied/satisfied and 81.82% (8/11) stated that effect on visit time was <10 min. CONCLUSIONS: Utilization of a total SB-monitoring tool can be useful in implementing safe steroid use and can lead to identification of possible adverse effects, intervention, and counseling.
